Impact of travel time on hospitalizations and patient cost responsibility by phase of care for older patients with cancer.

Authors

Courtney Williams

Courtney Williams

University of Alabama at Birmingham, Birmingham, AL

Courtney Williams, Kelly Kenzik, Maria Pisu, Stacey A. Ingram, Aidan Gilbert, Rodney Paul Rocconi, Gabrielle Betty Rocque

Organizations

University of Alabama at Birmingham, Birmingham, AL, University of Alabama at Birmingham, Birminghm, AL, University of South Alabama, Mobile, AL

Research Funding

Other

Background: Healthcare reimbursement changes are contributing to increased closures of community hospitals and oncology practices, which may lead cancer patients to travel greater distances for care. Limited data exists on the impact of travel time on hospitalization rates and patient cost responsibility by phase of care for older cancer patients. Methods: This was a secondary analysis of Medicare claims from 2012-2015 for cancer patients age ≥65 receiving care in the University of Alabama at Birmingham Cancer Community Network. Patient addresses were obtained from network data, hospitalizations from inpatient claims, and patient cost responsibility from inpatient, outpatient, skilled nursing facility, carrier, and durable medical equipment claims. Drive time was calculated from patient home to cancer care site (CCS). Phase of care-specific (initial, survivorship, end-of-life [EOL]) rates of hospitalizations overall and by CCS vs. other care site (OCS) were calculated per 100 person-years. Hierarchical linear models compared average monthly phase-specific costs by drive time to CCS. Results: Of 23,605 older cancer patients, median drive time to CCS was 32 minutes (IQR 18-59), with 24% driving ≥1 hour to CCS. Rates of hospitalizations by initial (n = 14,225), survivorship (n = 18,805), and EOL (n = 8,211) phases of care were 54, 26, and 301 per 100 person-years, respectively. Higher rates of hospitalizations at OCS vs. CCS were shown for patients traveling ≥1 hour to CCS (initial, survivorship, and EOL rate of 41 vs. 20, 21 vs. 6, and 220 vs. 95 per 100 person-years, respectively). Median monthly costs by phase were $401 (IQR $182-$814) for initial, $369 (IQR $123-$1046) for survivorship, and $2075 (IQR $1123-$3723) for EOL. Patients traveling ≥1 hour to their CCS had higher cost responsibility, with patients in initial, survivorship, and EOL phases having $303 (95% CI $130-$476), $75 (95% CI $46-$105), and $736 (95% CI $308-$1164) higher average costs per month than those traveling < 1 hour, respectively. Conclusions: Cancer patients traveling further to receive care are potentially vulnerable to higher cost responsibility and limited access to care if community hospitals close, especially at EOL.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2018 ASCO Quality Care Symposium

Session Type

Rapid Oral Abstract Session

Session Title

Rapid Abstract Session B

Track

Big Data Studies,Projects Relating to Equity, Value and Policy,Projects Relating to Patient Experience,Projects Relating to Safety,Technology and Innovation in Quality of Care

Sub Track

Measuring Value and Costs

Citation

J Clin Oncol 36, 2018 (suppl 30; abstr 37)

DOI

10.1200/JCO.2018.36.30_suppl.37

Abstract #

37

Abstract Disclosures

Similar Abstracts

Abstract

2021 ASCO Quality Care Symposium

Hospitalization burden and end-of-life (EOL) care in elderly patients with glioblastoma (GBM).

First Author: Laura Donovan

Abstract

2023 ASCO Quality Care Symposium

Loss to primary care provider follow-up among survivors five to seven years post-diagnosis.

First Author: Alexandra G. Peluso